Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes

Abstract

Sex, LIPC promoter variant, and ethnicity significantly contribute to the baseline variance in HL activity. Atorvastatin treatment in diabetic dyslipidemia results in a significant dose-dependent decrease in HL activity, regardless of sex or the LIPC promoter variant.